GSK Clinical Trial Pipeline — 232 Active Studies

Phase 1: 55, Phase 2: 80, Phase 3: 78, Other: 19

GSK's pipeline spans oncology, specialty medicines, and vaccines. In oncology, dostarlimab (Jemperli), a PD-1 inhibitor with approval in dMMR endometrial cancer, is expanding into multiple solid tumor indications. Their BCMA-targeting ADC, belantamab mafodotin (Blenrep), initially approved and then voluntarily withdrawn pending new trial data, is being re-evaluated in combination trials in multiple myeloma. In gynecologic oncology, niraparib (Zejula) for ovarian cancer is progressing through combination trials. GSK's vaccine pipeline is one of the industry's strongest — Shingrix (shingles), Arexvy (RSV), and next-generation pandemic influenza vaccines represent major development investments. In respiratory/inflammation, Nucala (mepolizumab, IL-5) is expanding across eosinophilic conditions.

• Oncology (PD-1, BCMA/ADC, PARP inhibitor)
• Vaccines (RSV, influenza, meningococcal)
• Respiratory / inflammation (IL-5, COPD)
• HIV (long-acting cabotegravir)
• Rare disease

• Jemperli (dostarlimab) — PD-1, gynecologic/dMMR cancers
• Blenrep (belantamab mafodotin) — BCMA ADC, myeloma (combination trials)
• Zejula (niraparib) — PARP inhibitor, ovarian cancer
• Nucala (mepolizumab) — IL-5, eosinophilic asthma/EGPA
• Arexvy — RSV vaccine, adults 60+
• GSK3745417 — STING agonist, solid tumors

GSK's Jemperli re-expansion program — building on the dMMR endometrial approval into broader MSI-high/dMMR tumor types and combination regimens — generates consistent new oncology registrations. Their PARP inhibitor niraparib combination trials are closely followed in gynecologic oncology. The belantamab combination re-introduction is one of the most watched programs in multiple myeloma.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to GSK (GlaxoSmithKline)'s registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: GSK (GlaxoSmithKline) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.